A new agent-specific signal within a familiar antibiotic class
A peer-reviewed study published September 3, 2026 in Frontiers in Medicine suggests that the risk profile for Stevens-Johnson syndrome and toxic epidermal necrolysis may not be uniform across beta-lactam antibiotics. The investigators combined a retrospective dermatology cohort with a large real-world electronic-health-record analysis and found a stronger SJS/TEN signal for ceftriaxone than for aminopenicillins, cefazolin, or cefuroxime.
That is potentially important because clinicians, patients, and even legal analyses sometimes discuss antibiotic risk primarily at the class level. The new study argues for more drug-specific pharmacovigilance within the beta-lactam and cephalosporin families.
What the researchers found
In the investigators' single-center cohort, only five SJS/TEN cases were identified, so the local numbers were small. Ceftriaxone accounted for two of those five cases. The authors therefore used the observation as a starting point for a much larger TriNetX analysis rather than treating the local cohort as definitive.
In propensity-matched real-world cohorts, SJS/TEN diagnoses occurring within 35 days of exposure were significantly less likely after aminopenicillins, cefazolin, and cefuroxime than after ceftriaxone. Compared with ceftriaxone as the reference, the odds ratios were 0.389 for aminopenicillins, 0.392 for cefazolin, and 0.300 for cefuroxime. Allopurinol, used as a positive control because of its well-established SJS/TEN risk, showed higher odds than ceftriaxone.
The authors conclude that ceftriaxone may occupy an intermediate position - stronger than the beta-lactam comparators studied, but below a classic high-risk drug such as allopurinol.
Why this is interesting for SJS/TEN causation
The study supports the idea that culprit-drug assessment should be substance-specific rather than simply class-specific. In a patient exposed to multiple antibiotics, the fact that several drugs belong to the beta-lactam family does not necessarily mean they carry identical SJS/TEN associations.
That does not make ceftriaxone automatically responsible whenever it appears in a medication list. Formal causality analysis still requires latency, dechallenge, competing drugs, infection-related alternative causes, prior exposure, and the clinical course. In hospitalized patients, those issues can be especially difficult because ceftriaxone is commonly given to seriously ill patients who may also receive many other medications.
Important limitations of the 2026 study
The authors expressly caution against overinterpreting the findings. Their local cohort was retrospective and included very few SJS/TEN cases. The TriNetX portion relied on routinely collected health-record data and ICD coding, which can misclassify SJS/TEN. Residual confounding is also important: ceftriaxone is often used in sicker inpatients, so severity of infection, sepsis, ICU care, malignancy, kidney disease, polypharmacy, and other factors could contribute to the observed association.
The analysis therefore identifies a risk signal; it does not measure a clean causal incidence rate and does not prove that ceftriaxone itself accounts for the difference.
The warning and product-identity problem
Current U.S. ceftriaxone labeling already reports isolated cases of severe cutaneous adverse reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis. Thus, the 2026 study does not reveal a completely unwarned adverse event.
Ceftriaxone is also heavily generic. For legal evaluation, pharmacy or hospital records identifying the actual manufacturer or labeler matter. Federal preemption can severely restrict warning claims against generic manufacturers, and a scientifically plausible causal association does not necessarily translate into a viable product-liability claim. Warning wording and timing, product identity, jurisdiction, prescribing circumstances, and alternative legal theories must be evaluated separately.
Why the study is still worth following
Even with those legal limitations, the study is useful for SJS/TEN case evaluation and for medical understanding. It suggests that individual beta-lactam agents may deserve different weights during culprit-drug analysis and that ceftriaxone should not be treated as interchangeable with every other cephalosporin for pharmacovigilance purposes.
For a patient who received ceftriaxone shortly before SJS/TEN, records should document the exact exposure window, other antibiotics and medications, indication for treatment, hospital status, renal function, infectious diagnoses, and the rationale used by treating physicians to identify the culprit medication.
What would strengthen the signal?
The ceftriaxone signal would become stronger with additional multicenter studies that better control for illness severity, inpatient status, infection type, ICU care, polypharmacy, and other confounders; prospectively adjudicated SJS/TEN diagnoses; independent replication in other databases; or regulatory action that changes the prominence or specificity of ceftriaxone's skin-reaction warning. Until then, the study is important enough to follow and explain, but not strong enough to transform every ceftriaxone-associated SJS/TEN case into a viable product claim.
Sources
Differential risk signals of cutaneous adverse drug reactions among beta-lactam antibiotics: ceftriaxone shows increased signals for SJS/TEN in clinical and real-world cohorts, Frontiers in Medicine DOI: 10.3389/fmed.2026.1875934. Direct source
DailyMed - Ceftriaxone sodium injection labeling Direct source